STAAR Surgical (STAA) Stock Price, News & Analysis

Company Overview

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Key Stats

• Today's Range: $22.22 to $23.16
• 50-Day Range: $22.11 to $28.98
• 52-Week Range: $15.59 to $35.87
• Volume: 798,065 shs
• Average Volume: 802,282 shs
• Market Capitalization: $1.16 billion
• P/E Ratio: 329.62
• Dividend Yield: N/A
• Price Target: $28.40
• Consensus Rating: Reduce

STAAR Surgical Stock Analysis - MarketRank™

STAAR Surgical scored higher than 67% of companies evaluated by MarketBeat, and ranked 270th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Reduce

Consensus Rating

STAAR Surgical has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on no strong buy ratings, 2 buy ratings, 8 hold ratings, and 3 sell ratings.

Upside Potential

STAAR Surgical has a consensus price target of $28.40, representing about 23.1% upside from its current price of $23.07.

Amount of Analyst Coverage

STAAR Surgical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 38.46%

Earnings Growth

Earnings for STAAR Surgical are expected to grow by 38.46% in the coming year, from $0.39 to $0.54 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of STAAR Surgical is 329.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.99.

Price to Earnings Ratio vs. Sector

The P/E ratio of STAAR Surgical is 329.62, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.30.

Price to Book Value per Share Ratio

STAAR Surgical has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.15% of the float of STAAR Surgical has been sold short.

Short Interest Ratio / Days to Cover

STAAR Surgical has a short interest ratio ("days to cover") of 5.71.

Change versus previous month

Short interest in STAAR Surgical has recently decreased by 2.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

STAAR Surgical does not currently pay a dividend.

Dividend Growth

STAAR Surgical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.41

News Sentiment

STAAR Surgical has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for STAAR Surgical this week, compared to 6 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, STAAR Surgical insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.90% of the stock of STAAR Surgical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.70% of the stock of STAAR Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/15/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:STAA
• CIK: 718937
• Web: www.staar.com
• Phone: (626) 303-7902
• Fax: 626-303-2962
• Employees: 957
• Year Founded: 1982

Price Target and Rating

• Average Price Target for STAAR Surgical: $28.40
• High Price Target: $37.00
• Low Price Target: $13.00
• Potential Upside/Downside: +23.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.07
• Trailing P/E Ratio: 329.62
• Forward P/E Ratio: 59.15
• P/E Growth: N/A
• Net Income: -$80.45 million
• Net Margins: 1.13%
• Pretax Margin: 5.12%
• Return on Equity: 9.05%
• Return on Assets: 6.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.66
• Quick Ratio: 4.03

Sales & Book Value

• Annual Sales: $339.59 million
• Price / Sales: 3.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.92 per share
• Price / Book: 3.33

Miscellaneous

• Outstanding Shares: 50,144,000
• Free Float: 30,137,000
• Market Cap: $1.16 billion
• Optionable: Optionable
• Beta: 1.21